CliffBio
biologic

Idacio

adalimumab-aacf

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameIdacio
Active ingredientadalimumab-aacf
Strength40MG/0.8ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2024
Marketing statusRx

More from Fresenius Kabi

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.